N-Methyl-3,4-methylenedioxyamphetamine clinical trials
Also written MDMA.
Its developmentBy 4 companies, company by company29 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.Includes 2 studies of Midomafetamine hydrochloride.
How each study uses N-Methyl-3,4-methylenedioxyamphetamine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the N-Methyl-3,4-methylenedioxyamphetamine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
91 studies that test it; most in 2025 (12)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 8 |
| 2024 | 7 |
| 2025 | 12 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 62
Lykos Therapeutics (24) · University Hospital, Basel, Switzerland (19) · University of Chicago (7) · Resilient Pharmaceuticals (2) · Emory University (2) · Yale University (2) · Johns Hopkins University (2) · Sunstone Medical (2)
Often tested with
Tested in the same studies.
Psilocybin (4) · Methylphenidate (4) · Lysergic Acid Diethylamide (3) · Methamphetamine (2) · Bean (1) · Tenamfetamine (1) · Carvedilol (1) · Doxazosin (1)
Related medicines
As reviewed, each with the page that says it.
- One of Psychedelics source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 11, 1 in phase 3
Studies that test N-Methyl-3,4-methylenedioxyamphetamine, phase 3 first.
- Mar 2027MDMA-assisted Massed Prolonged Exposure for PTSDPhase 3 · Healing Breakthrough
- Dec 2026MDMA-assisted Therapy for FibromyalgiaEarly Phase 1 · Spaulding Rehabilitation Hospital
- Dec 2026Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy ControlsNot applicable · University Hospital, Basel, Switzerland
- Dec 2026MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)Phase 2 · Carolyn Rodriguez
- Mar 2027Tolerability of MDMA in SchizophreniaPhase 1/2 · Anya Bershad, MD, PhD
- Mar 2027Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy ParticipantsPhase 1 · University Hospital, Basel, Switzerland
- Apr 2027MDMA Therapy in Veterans With PTSDPhase 2 · Sunstone Medical
- May 2027MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress DisorderPhase 2 · Patricia Suppes
- Jun 2027MDMA in Borderline Personality DisorderPhase 2 · Yale University
- Jun 2027Investigation of Psychedelic Effects in Psychoactive SubstancesPhase 1 · Johns Hopkins University
Studies
Open first, then newest update. How each study uses N-Methyl-3,4-methylenedioxyamphetamine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 91
- MDMA in Borderline Personality DisorderRecruitingPhase 2Yale UniversityNCT06683014Written as MDMAHow we know
- Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSDRecruitingPhase 2Guy SchusheimNCT05732155Written as methylenedioxymethamphetamineHow we know
- Dose Optimization of MDMA-Assisted Therapy for PTSDRecruitingPhase 2Bronx VA Medical CenterNCT06418178Written as MidomafetamineHow we know
- Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)RecruitingPhase 1Johns Hopkins UniversityNCT06989957Written as MDMAHow we know
- MDMA-assisted Therapy for FibromyalgiaRecruitingEarly Phase 1Spaulding Rehabilitation HospitalNCT06066853Written as MDMAHow we know
- MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress DisorderRecruitingPhase 2Stephen Robert MarderNCT05790239Written as 3,4-methylenedioxymethamphetamineHow we know
- Ecstasy to Alleviate SEvere Chronic Neuropathic Pain TrialRecruitingPhase 2Unity Health TorontoNCT07301632Written as 3,4-MethylenedioxymethamphetamineHow we know
- Tolerability of MDMA in SchizophreniaRecruitingPhase 1/2Anya Bershad, MD, PhDNCT05770375Written as MDMA 40mgHow we know
- MDMA Plus Exposure Therapy for PTSDEnrolling by invitationPhase 2Emory UniversityNCT05746572Written as MDMAHow we know
- MDMA Therapy in Veterans With PTSDRecruitingPhase 2Sunstone MedicalNCT07569159Written as MDMAHow we know
- MDMA-Assisted Massed Exposure Therapy for PTSDRecruitingPhase 2Emory UniversityNCT07288151Written as 3,4-Methylenedioxymethamphetamine (MDMA)How we know
- MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First RespondersNot yet recruitingPhase 2Nautilus SanctuaryNCT05455996Written as MDMAHow we know
- MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant OtherRecruitingPhase 2Sunstone MedicalNCT05584826Written as MDMAHow we know
- Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy ParticipantsRecruitingPhase 1University Hospital, Basel, SwitzerlandNCT07494214Written as MDMA 25 mgHow we know
- MDMA-Assisted Therapy for Mental Healthcare ProvidersRecruitingPhase 1Rachel YehudaNCT07102576Written as MDMA HydrochlorideHow we know
- Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 EventsRecruitingPhase 2Sheba Medical CenterNCT07469098Written as MDMA HClHow we know
- MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)RecruitingPhase 2Carolyn RodriguezNCT05783817Written as 3,4-Methyl enedioxy methamphetamineHow we know
- Investigation of Psychedelic Effects in Psychoactive SubstancesRecruitingPhase 1Johns Hopkins UniversityNCT06772753Written as Methylenedioxymethamphetamine (MDMA)How we know
- MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress DisorderRecruitingPhase 2Patricia SuppesNCT05837845Written as MDMAHow we know
- The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy TrainingEnrolling by invitationNot applicableFelix MuellerNCT05570708Written as MDMA, LSD, psilocybinHow we know
See all 91 studies that test N-Methyl-3,4-methylenedioxyamphetamine →
As the comparator · 4 — what is tested is compared with N-Methyl-3,4-methylenedioxyamphetamine
- Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3CompletedPhase 4Fundación HuéspedNCT04880395Written as Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)How we know
- Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy SubjectsCompletedPhase 1University Hospital, Basel, SwitzerlandNCT05523401Written as 3,4-methylenedioxymethamphetamineHow we know
- Abuse Potential and Human Pharmacology of MethyloneStatus unknownPhase 1Germans Trias i Pujol HospitalNCT05488171Written as 3,4-methylenedioxymethamphetamineHow we know
- Abuse Liability and Human Pharmacology of MephedroneCompletedPhase 1Parc de Salut MarNCT02232789Written as 3,4-methylenedioxymethamphetamineHow we know
Codes
What other systems call N-Methyl-3,4-methylenedioxyamphetamine · ClinicalTrials.gg INT008652
- MeSH (NLM) D018817N-Methyl-3,4-methylenedioxyamphetamineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KE1SEN21RMMIDOMAFETAMINEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D018817 | N-Methyl-3,4-methylenedioxyamphetamine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KE1SEN21RM | MIDOMAFETAMINE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.